Fabrice Zobel Lekeumo Cheuyem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fabrice Zobel Lekeumo Cheuyem has a total of 325 co-authors. Here are the top co-authors by number of shared publications:
- Rick Tchamani
Community Research Academy & Consulting, Douala, Cameroon
27 shared publications - Chabeja Achangwa
Department of Public Health, Faculty of Medical Sciences, University of West Indies, Bridgetown, Barbados
25 shared publications - Adidja Amani
Department of Public Health, Faculty of Medicine and Biomedical Sciences, The University of Yaounde I
21 shared publications - Innocent Takougang
Department of Public Health, Faculty of Medicine and Biomedical Sciences, The University of Yaounde 1, Yaounde, Cameroon
18 shared publications - Ariane Nouko
Department of Public Health, Faculty of Medicine and Biomedical Sciences, The University of Yaounde 1, Yaounde, Cameroon
15 shared publications - Solange Dabou
Department of Biochemistry, University of Dschang, Dschang, Cameroon
11 shared publications
Latest Publications
- Open Access
Human immunodeficiency virus and tuberculosis coinfection prevalence and treatment outcomes in Cameroon: a systematic review and meta-analysis
Background: Human immunodeficiency virus (HIV) and tuberculosis (TB) form one of the deadliest syndemics, and sub-Saharan Africa bears over 80% of HIV-associated TB deaths. In Cameroon, evidence on HIV/TB coinfection remains unsynthesized across regions and populations, obscuring the national burden. Hence, we estimated the prevalence of HIV/TB coinfection and treatment outcomes in Cameroon. Methods: Following PRISMA 2020 (PROSPERO: CRD420261399169), we searched PubMed, Scopus, Embase, Web of Science, Cochrane Library, African Journals Online, and grey literature for English- and French-language studies conducted in Cameroon. Reports were independently screened, their data extracted, and their methodology appraised using Joanna Briggs Institute tools. Random-effects models pooled prevalence, treatment outcomes, and adjusted odds ratios. Heterogeneity was assessed with I ². Results: Seventy studies (1995–2023) were included, 87.1% at low risk of bias. Pooled HIV prevalence among TB patients was 29.2% (95% CI: 26.3–32.3; 67 studies; n=57,169; I ² = 97.8%), with no significant evidence of publication bias. Prevalence was higher from 2007 onwards (29.9%; 62 studies; n=55,358) than before (20.5%; 5 studies; n=1,811). It was highest in the North-West (41.9%; 7 studies; n=6,324) versus Littoral (25.0%; 15 studies; n=10,419) and West (23.8%; 6 studies; n=4,206); and in extrapulmonary TB (42.3%; 3 studies; n=371) versus mixed forms (37.7%; 21 studies; n=37,239) and pulmonary TB (23.9%; 37 studies; n=16,096) (all p <0.05). Among coinfected patients, pooled treatment success was 75.9% (95% CI: 70.4–80.8; 8 studies; n=4,230), mortality 21.1% (95% CI: 11.9–34.7; 10 studies; n=4,403), loss to follow-up 7.7% (95% CI: 4.3–13.3; 5 studies; n=3,103), and treatment failure 0.3% (95% CI: 0.1–1.5; 6 studies; n=3,520). Lack of antiretroviral therapy (ART) increased the odds of unfavorable outcomes (AOR = 1.90; 95% CI: 1.15–3.12; 2 studies). Conclusions: Approximately three in ten TB patients in Cameroon are coinfected with HIV, with marked regional and clinical variation. Treatment success remains below national targets. Strengthening TB-HIV service integration, routine HIV testing, and timely ART initiation and continuation is essential to reduce the HIV-associated TB morbidity and mortality in the country.
Open AccessHuman immunodeficiency virus and tuberculosis coinfection prevalence and treatment outcomes in Cameroon: a systematic review and meta-analysis
Background: Human immunodeficiency virus (HIV) and tuberculosis (TB) form one of the deadliest syndemics, and sub-Saharan Africa bears over 80% of HIV-associated TB deaths. In Cameroon, evidence on HIV/TB coinfection remains unsynthesized across regions and populations, obscuring the national burden. Hence, we estimated the prevalence of HIV/TB coinfection and treatment outcomes in Cameroon. Methods: Following PRISMA 2020 (PROSPERO: CRD420261399169), we searched PubMed, Scopus, Embase, Web of Science, Cochrane Library, African Journals Online, and grey literature for English- and French-language studies conducted in Cameroon. Reports were independently screened, their data extracted, and their methodology appraised using Joanna Briggs Institute tools. Random-effects models pooled prevalence, treatment outcomes, and adjusted odds ratios. Heterogeneity was assessed with I ². Results: Seventy studies (1995–2023) were included, 87.1% at low risk of bias. Pooled HIV prevalence among TB patients was 29.2% (95% CI: 26.3–32.3; 67 studies; n=57,169; I ² = 97.8%), with no significant evidence of publication bias. Prevalence was higher from 2007 onwards (29.9%; 62 studies; n=55,358) than before (20.5%; 5 studies; n=1,811). It was highest in the North-West (41.9%; 7 studies; n=6,324) versus Littoral (25.0%; 15 studies; n=10,419) and West (23.8%; 6 studies; n=4,206); and in extrapulmonary TB (42.3%; 3 studies; n=371) versus mixed forms (37.7%; 21 studies; n=37,239) and pulmonary TB (23.9%; 37 studies; n=16,096) (all p <0.05). Among coinfected patients, pooled treatment success was 75.9% (95% CI: 70.4–80.8; 8 studies; n=4,230), mortality 21.1% (95% CI: 11.9–34.7; 10 studies; n=4,403), loss to follow-up 7.7% (95% CI: 4.3–13.3; 5 studies; n=3,103), and treatment failure 0.3% (95% CI: 0.1–1.5; 6 studies; n=3,520). Lack of antiretroviral therapy (ART) increased the odds of unfavorable outcomes (AOR = 1.90; 95% CI: 1.15–3.12; 2 studies). Conclusions: Approximately three in ten TB patients in Cameroon are coinfected with HIV, with marked regional and clinical variation. Treatment success remains below national targets. Strengthening TB-HIV service integration, routine HIV testing, and timely ART initiation and continuation is essential to reduce the HIV-associated TB morbidity and mortality in the country.
- Open Access
Tuberculosis treatment outcome in Cameroon: a systematic review and meta-analysis
Background: Tuberculosis (TB) remains a major public health challenge in Cameroon, yet national evidence on treatment outcomes across the full spectrum of routine care is limited. This systematic review and meta-analysis estimated pooled proportions of treatment success, mortality, treatment failure and loss to follow-up (LTFU) among TB patients in Cameroon, and identified predictors of unfavorable outcomes. Methods: PubMed, Embase, Scopus, Web of Science, African Journals Online and the Cochrane Library were searched, supplemented by Google Scholar and reference-list screening. Observational studies conducted in Cameroon reporting at least one WHO-defined treatment outcome were eligible. Pooled proportions and adjusted odds ratios (AOR) were estimated with random-effects models meta-analysis. Data were analyzed using R Statistics version 4.6.1. Results: Thirty-two studies (25 cohorts, 7 cross-sectional), conducted between 1998 and 2022 across six of Cameroon’s ten regions, were included. Pooled treatment success was 78.2% (95% CI: 73.8–82.1; 27 reports; 71,784 participants; I² = 98.2%), mortality 8.1% (95% CI: 5.5–11.7; 25 reports; 71,870 participants; I² = 97.8%), treatment failure 0.9% (95% CI: 0.5–1.4; 26 reports; 71,389 participants; I² = 89.1%) and LTFU 6.8% (95% CI: 5.0–9.1; 26 reports; 70,768 participants; I² = 98.6%). Mortality was highest in the South-West (16.2%) and among TB/HIV-coinfected patients (30.5%), and lowest among children (5.0%). Treatment success was lowest in the Littoral (71.1%) and among TB/HIV-coinfected patients (60.8%) and highest among multidrug-resistant TB (89.3%) and pediatric patients (86.8%). Treatment failure significantly declined from 2.9% before 2005 to 0.5% from 2020 onward ( p < 0.001). Significant predictors of unfavorable outcomes were HIV positivity (AOR = 2.57; 95% CI: 1.86–3.55), previous TB treatment (AOR = 1.99; 95% CI: 1.40–2.84), male sex (AOR = 1.67; 95% CI: 1.45–1.92), age ≤40 years (AOR = 1.45; 95% CI: 1.06–1.98) and absence of antiretroviral therapy (AOR = 1.71; 95% CI: 1.15–2.54). Conclusions: TB treatment outcomes in Cameroon remain suboptimal, with nearly one in five patients not achieving treatment success and high mortality among TB/HIV-coinfected individuals. Strengthening TB/HIV service integration, early antiretroviral therapy initiation, targeted support for previously treated patients and men, and improved retention in care are needed. Systematic review registration number: CRD420261404490
Open AccessTuberculosis treatment outcome in Cameroon: a systematic review and meta-analysis
Background: Tuberculosis (TB) remains a major public health challenge in Cameroon, yet national evidence on treatment outcomes across the full spectrum of routine care is limited. This systematic review and meta-analysis estimated pooled proportions of treatment success, mortality, treatment failure and loss to follow-up (LTFU) among TB patients in Cameroon, and identified predictors of unfavorable outcomes. Methods: PubMed, Embase, Scopus, Web of Science, African Journals Online and the Cochrane Library were searched, supplemented by Google Scholar and reference-list screening. Observational studies conducted in Cameroon reporting at least one WHO-defined treatment outcome were eligible. Pooled proportions and adjusted odds ratios (AOR) were estimated with random-effects models meta-analysis. Data were analyzed using R Statistics version 4.6.1. Results: Thirty-two studies (25 cohorts, 7 cross-sectional), conducted between 1998 and 2022 across six of Cameroon’s ten regions, were included. Pooled treatment success was 78.2% (95% CI: 73.8–82.1; 27 reports; 71,784 participants; I² = 98.2%), mortality 8.1% (95% CI: 5.5–11.7; 25 reports; 71,870 participants; I² = 97.8%), treatment failure 0.9% (95% CI: 0.5–1.4; 26 reports; 71,389 participants; I² = 89.1%) and LTFU 6.8% (95% CI: 5.0–9.1; 26 reports; 70,768 participants; I² = 98.6%). Mortality was highest in the South-West (16.2%) and among TB/HIV-coinfected patients (30.5%), and lowest among children (5.0%). Treatment success was lowest in the Littoral (71.1%) and among TB/HIV-coinfected patients (60.8%) and highest among multidrug-resistant TB (89.3%) and pediatric patients (86.8%). Treatment failure significantly declined from 2.9% before 2005 to 0.5% from 2020 onward ( p < 0.001). Significant predictors of unfavorable outcomes were HIV positivity (AOR = 2.57; 95% CI: 1.86–3.55), previous TB treatment (AOR = 1.99; 95% CI: 1.40–2.84), male sex (AOR = 1.67; 95% CI: 1.45–1.92), age ≤40 years (AOR = 1.45; 95% CI: 1.06–1.98) and absence of antiretroviral therapy (AOR = 1.71; 95% CI: 1.15–2.54). Conclusions: TB treatment outcomes in Cameroon remain suboptimal, with nearly one in five patients not achieving treatment success and high mortality among TB/HIV-coinfected individuals. Strengthening TB/HIV service integration, early antiretroviral therapy initiation, targeted support for previously treated patients and men, and improved retention in care are needed. Systematic review registration number: CRD420261404490
- Open Access
- 16 October 2026
- Published by Springer Nature in BMC Research Notes
Vaccine uptake patterns for COVID-19 and cholera among healthcare workers: a cross-sectional study in Yaoundé-Cameroon
- 16 October 2026
- Published by Springer Nature in BMC Research Notes
Open AccessVaccine uptake patterns for COVID-19 and cholera among healthcare workers: a cross-sectional study in Yaoundé-Cameroon
- 9 October 2026
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 8 (1) , 516
Prevalence of Obesity and Overweight Among Adults Living with Type 2 Diabetes Mellitus in Cameroon: a Systematic Review and Meta-analysis
- 9 October 2026
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 8 (1) , 516
Prevalence of Obesity and Overweight Among Adults Living with Type 2 Diabetes Mellitus in Cameroon: a Systematic Review and Meta-analysis
- Open Access
- 8 October 2026
- Published by Springer Nature in BMC Infectious Diseases
Treatment outcomes of drug-resistant Mycobacterium tuberculosis disease in Cameroon: a systematic review and meta-analysis
- 8 October 2026
- Published by Springer Nature in BMC Infectious Diseases
Open AccessTreatment outcomes of drug-resistant Mycobacterium tuberculosis disease in Cameroon: a systematic review and meta-analysis
- Open Access
- 22 August 2026
- Published by Springer Nature in BMC Research Notes
Meningitis vaccination campaign in the context of COVID-19 in Cameroon
- 22 August 2026
- Published by Springer Nature in BMC Research Notes
Open AccessMeningitis vaccination campaign in the context of COVID-19 in Cameroon
- Open Access
- 14 August 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Human papillomavirus vaccine acceptability in Cameroon: a systematic review and meta-analysis
- 14 August 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Open AccessHuman papillomavirus vaccine acceptability in Cameroon: a systematic review and meta-analysis
- Open Access
Treatment outcomes of drug-resistant Mycobacterium tuberculosis infection in Cameroon: a systematic review and meta-analysis
Background: Drug-resistant tuberculosis (DR-TB) remains a major challenge to tuberculosis control in sub-Saharan Africa. Cameroon faces substantial challenges in managing DR-TB; however, national evidence on treatment outcomes remains unsynthesized. This systematic review and meta-analysis aimed to estimate pooled treatment outcomes, adverse drug events (ADEs), and predictors of unfavorable outcomes among patients with DR-TB in Cameroon. Methods: This systematic review and meta-analysis followed the PRISMA 2020 guidelines. PubMed, Scopus, Embase, Web of Science, the Cochrane Library, African Journals Online. Google Scholar and reference lists were also searched. Studies reporting World Health Organization-defined treatment outcomes among patients with DR-TB were included. Random-effects meta-analyses using generalized linear mixed models with logit transformation were performed. Heterogeneity was assessed using the I ² statistic, and publication bias and sensitivity analyses were conducted. Results: Fifteen studies conducted between 1998 and 2022 were included. The pooled mortality rate was 6.8% (95% CI: 4.7–9.7; 14 reports; n = 2,351 participants), loss to follow-up was 4.1% (95% CI: 2.8–6.1; 12 studies; n = 2,244 participants), and treatment failure was 5.0% (95% CI: 1.1–19.8; 12 studies; n = 2,050 participants). The pooled treatment success rate was 74.2% (95% CI: 60.4–84.4; 13 reports; n = 2,146 participants). Treatment success improved over time and was higher with modified regimens (87.2%; 95% CI: 83.8–89.9; 3 studies; n = 460 participants) than with standard regimens (68.8%; 95% CI: 52.2–81.6; 10 studies; n = 1,686 participants). Among patients with multidrug-resistant-TB, the pooled prevalence of adverse drug events was 70.8% (95% CI: 40.2–89.7; 3 studies; n = 251 participants), with ototoxicity (41.9%; 95% CI: 23.7–62.6; 3 studies; n = 251 participants) and gastrointestinal disorders (40.9%; 95% CI: 25.5–58.2; 2 studies; n = 172 participants) being the most common events. HIV co-infection was significantly associated with unfavorable treatment outcomes (pooled OR = 2.76; 95% CI: 1.95–3.93; 6 studies), and male gender was also associated with increased odds of unfavorable outcomes (OR = 1.73; 95% CI: 1.25–2.40; 5 studies). Conclusions: Approximately three-quarters of patients with DR-TB in Cameroon achieved successful treatment, although mortality, treatment failure, and adverse drug events remain important concerns. Strengthening pharmacovigilance, integrated TB/HIV care, and the implementation of effective all-oral regimens are essential to improve treatment outcomes. Systematic review registration number: CRD420261404490.
Open AccessTreatment outcomes of drug-resistant Mycobacterium tuberculosis infection in Cameroon: a systematic review and meta-analysis
Background: Drug-resistant tuberculosis (DR-TB) remains a major challenge to tuberculosis control in sub-Saharan Africa. Cameroon faces substantial challenges in managing DR-TB; however, national evidence on treatment outcomes remains unsynthesized. This systematic review and meta-analysis aimed to estimate pooled treatment outcomes, adverse drug events (ADEs), and predictors of unfavorable outcomes among patients with DR-TB in Cameroon. Methods: This systematic review and meta-analysis followed the PRISMA 2020 guidelines. PubMed, Scopus, Embase, Web of Science, the Cochrane Library, African Journals Online. Google Scholar and reference lists were also searched. Studies reporting World Health Organization-defined treatment outcomes among patients with DR-TB were included. Random-effects meta-analyses using generalized linear mixed models with logit transformation were performed. Heterogeneity was assessed using the I ² statistic, and publication bias and sensitivity analyses were conducted. Results: Fifteen studies conducted between 1998 and 2022 were included. The pooled mortality rate was 6.8% (95% CI: 4.7–9.7; 14 reports; n = 2,351 participants), loss to follow-up was 4.1% (95% CI: 2.8–6.1; 12 studies; n = 2,244 participants), and treatment failure was 5.0% (95% CI: 1.1–19.8; 12 studies; n = 2,050 participants). The pooled treatment success rate was 74.2% (95% CI: 60.4–84.4; 13 reports; n = 2,146 participants). Treatment success improved over time and was higher with modified regimens (87.2%; 95% CI: 83.8–89.9; 3 studies; n = 460 participants) than with standard regimens (68.8%; 95% CI: 52.2–81.6; 10 studies; n = 1,686 participants). Among patients with multidrug-resistant-TB, the pooled prevalence of adverse drug events was 70.8% (95% CI: 40.2–89.7; 3 studies; n = 251 participants), with ototoxicity (41.9%; 95% CI: 23.7–62.6; 3 studies; n = 251 participants) and gastrointestinal disorders (40.9%; 95% CI: 25.5–58.2; 2 studies; n = 172 participants) being the most common events. HIV co-infection was significantly associated with unfavorable treatment outcomes (pooled OR = 2.76; 95% CI: 1.95–3.93; 6 studies), and male gender was also associated with increased odds of unfavorable outcomes (OR = 1.73; 95% CI: 1.25–2.40; 5 studies). Conclusions: Approximately three-quarters of patients with DR-TB in Cameroon achieved successful treatment, although mortality, treatment failure, and adverse drug events remain important concerns. Strengthening pharmacovigilance, integrated TB/HIV care, and the implementation of effective all-oral regimens are essential to improve treatment outcomes. Systematic review registration number: CRD420261404490.
- Open Access
- 27 July 2026
- Published by Springer Nature in BMC Health Services Research
- Vol. 26 (1)
Humanization of care: a geospatial analysis of key indicators of quality and safety of health care and service in the Centre region, Cameroon
Integrating the principles of humanized care into healthcare systems is critical to promoting optimal well-being. In a context of limited resources, improv
- 27 July 2026
- Published by Springer Nature in BMC Health Services Research
- Vol. 26 (1)
Open AccessHumanization of care: a geospatial analysis of key indicators of quality and safety of health care and service in the Centre region, Cameroon
Integrating the principles of humanized care into healthcare systems is critical to promoting optimal well-being. In a context of limited resources, improv